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Abstract
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the two major forms of primary liver
cancers (PLC), accounting for approximately 90% and 5% respectively. The incidence of each is increasing rapidly in
the western world, however our knowledge of the underlying mechanisms remains limited and the outcome,
dismal. The etiologies of each vary geographically; nevertheless, chronic inflammation has been identified in more
than 80% of the cases and appears to be a key mediator in altering the liver microenvironment, increasing the risk
of carcinogenesis. However, since not all HCC and especially ICC cases have a recognized risk factor, there are
currently two proposed models for liver carcinogenesis. The clonal evolution model demonstrates a multi-step
process of tumor development from precancerous lesions to metastatic carcinoma, arising from the accumulation
of genetic and epigenetic changes in a cell in the setting of chronic inflammation. While the majority of cases do
occur as a consequence of chronic inflammation, most individuals with chronic infection do not develop PLC,
suggesting the involvement of individual genetic and environmental factors. Further, since hepatocytes and
cholangiocytes both have regenerative potential and arise from the same bi-potential progenitor cell, the more
recently proposed cancer stem cell model is gaining its due attention. The integration of these models and the
constant improvement in molecular profiling platforms is enabling a broader understanding of the mechanisms
underlying these two devastating malignancies, perhaps moving us closer to a new world of molecularly-informed
personalized medicine.
Introduction
Primary liver cancer (PLC) is the fifth most common
cancer worldwide and the third most deadly, with
approximately 600,000 deaths annually. Hepatocellular
carcinoma (HCC), a primary malignancy of the hepato-
cyte, accounts for approximately 85% to 90% of all PLC,
out of which 80% of HCC cases occur in either sub-
Saharan Africa or in eastern Asia [1,2]. Cholangiocarci-
noma (CCA), a malignancy of cholangiocytes in the bili-
ary epithelium, is the second most common form and
accounts for about 5% to 10% of PLC. CCA is categor-
ized as intrahepatic or extrahepatic according to the
anatomic location of the tumor. Since intrahepatic cho-
langiocarcinomas (ICC) usually present in small biliary
ducts or ductules they are considered a PLC, compared
to extrahepatic cholangiocarcinomas which are a form
of biliary tract cancer. The incidence of CCA varies with
regards to the two forms; however, for purposes of this
review we will address ICC, which has the highest inci-
dence in eastern Asia, particularly Thailand, with an
increasing risk ratio in the western world [3-5]. The
remaining PLC subtypes, which account for less than
5% of cases, are fibrolamellar HCC, hepatoblastoma,
angiosarcoma, epithelioid hemangioendothelioma and
hepatocellular adenoma.
Risk factors that lead to the multistep development of
HCC are well known and it is established that approxi-
mately 80% of HCC cases develop in individuals suffer-
ing from chronic hepatitis B or C viral infection (HBV
or HCV), cirrhosis, and also those with a high exposure
to aflatoxin-b1 (AFB). HCC is particularly attributed to
these exposures due to the extensive oxidative stress
and release of inflammatory cytokines induced by viral
infection in the setting of liver inflammation. Diabetes,
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ciated with the development of HCC, but with reduced
frequency [6-8]. Currently, individuals at risk for HCC
are routinely screened by ultrasonography and alpha-
fetoprotein (AFP) levels but most patients are still diag-
nosed with an advanced disease stage and therefore a
5-year survival for the majority of HCC patients’ remains
dismal [9,10]. Due to the high variability in AFP evalua-
tion, affected by the specificity of the test, ethnic back-
grounds and tumor size, an improvement in screening
procedures is highly awaited. Furthermore, the impair-
ment of liver function and the expression of multi-drug
resistance genes render HCC treatment difficult [11].
This review discusses the mechanistic changes that occur
during the development of HCC and the potential targets
that are being investigated for new screening techniques,
with the hope that this will lead to a more personalized
treatment regimen to improve patient outcome.
Risk factors for ICC, on the other hand, are not so
well established given that approximately 90% of ICC
patients lack a recognized risk factor for the disease
[12]. Furthermore, ICC cases appear to develop in
otherwise healthy livers, with only 10% resulting from
chronic inflammation [3]. Nevertheless, relatively strong
CCA associations have been established with primary
sclerosing cholangitis (PSC) [13-15], liver fluke infesta-
tions [14,16] and hepatolithiasis [3]. Other possible, but
not well characterized associations may also exist with
HBV or HCV infection [17-19] and alcohol consump-
tion [20,21]. The molecular interactions and genomic
alterations in cholangiocytes that drive the development
of CCA are not clear and the absence of specific symp-
toms and diagnostic tests mak et h ed i s e a s ed i f f i c u l tt o
identify in premalignant stages. Currently, 5-year survi-
val rate for ICC cases remains below 5% [3], with the
only hope for improved survival being complete resec-
tion of the tumor. This underscores the need for
increased research in this field and for the development
of improved diagnostic criteria and treatment options.
The increased utilization of genome-wide association
studies (GWAS) will be particularly useful to identify
large-scale genetic variants in PLCs, particularly cholan-
giocarcinoma, since so little is currently understood.
As mentioned, in this review we will describe the cur-
rent understanding in the molecular mechanisms, speci-
fically the genetic, epigenetic and signaling alterations
that take place, which give rise to the majority of PLC
cases observed, separated by HCC and ICC. Further-
more, it is interesting to note the two models for tumor-
igenesis, a step-wise clonal evolution model and a
cancer stem cell (CSC) model, that have arisen as a con-
sequence of our improved understanding in this field.
How these models will impact PLC cases in the clinical
setting will provide for a stimulating discussion.
Hepatocellular Carcinoma
Altered signaling pathways in HCC at the genomic and
transcriptomic levels
In a setting of chronic inflammation, the organ microen-
vironment experiences a variety of molecular changes
that, in fact, often stem from the process and conse-
quence of inflammation. In liver, cytokines and reactive
oxygen and nitrogen species produced by inflammatory
cells have been shown to mediate liver damage and
induce the liver’s regenerative response [22-26]. This
predisposes the proliferating cell to a variety of genetic
changes at the genomic and transcriptional levels.
Genomic alterations
Large-scale quantitative comparisons of HCC tumors to
non-tumors by the use of comparative genomic hybridi-
zation (CGH) arrays and loss of heterozygosity (LOH)
has revealed the occurrence of chromosomal and micro-
satellite instability in HCC. The most frequently deleted
chromosomes arms are 1p, 4q, 6q, 8p, 9p, 13q, 16p, 16q
and 17p and regional gains are most often observed in
1q, 6p, 8q and 17q [27,28], which, in general corre-
sponds to autosome arms that contain allelic deletions
identified by LOH: 1p, 1q, 4q, 5q, 6q, 8p, 9p, 13q, 16p,
16q and 17p [27,29,30]. Unrelated to tumor size, indivi-
dual HCCs can represent multiple allelic deletions and
chromosomal gains and losses, which can accumulate
during successive cell proliferation events and results in
a heterogeneous mixture of genomic aberrations [31].
The heterogeneity of tumors can help to identify tumor
origin and due to the sensitivity of CGH and SNP
arrays, genomic alterations can be used as fingerprints
to identify whether a tumor is a recurrent event or a
second primary tumor [32,33]. The frequent loss of
chromosome regions observed by LOH and SNP arrays
has revealed the concomitant loss or mutation of tumor
suppressor genes such as TP53 (p53), retinoblastoma
RB1 (Rb) [34,35], CDKN2A (p16
INK4A) [29,36] and insu-
lin-like growth factor-2 receptor IGF-2R [37,38], which
are strongly associated with carcinogenetic signaling
pathways [29,34,39,40]. Gain of function mutations have
also been observed in HCC, for example mutations in
CTNNBI (b-catenin), which results in the deregulation
of similar signaling pathways in HCC [41,42].
TP53 gene encodes the p53 protein which plays a
pivotal role in the DNA-damage response network,
including cell cycle arrest, apoptosis, DNA repair and
cellular senescence. Therefore, it is not surprising that
TP53 loss of function mutations or allelic deletions in
chromosome 17p are commonly associated with human
carcinogenesis [43], and depending on the extent of
damage, p53 can either regulate the production of anti-
oxidant genes to initiate DNA repair, or induce apopto-
sis through the activation of pro-oxidant genes[29].
AFB1 is a particular mutagen of TP53, causing G:C
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(converting arginine to serine), and the rate of TP53
R249S mutation may be accelerated in the presence of
viral infection [44,45]. HBV encodes a viral protein,
HBx, which can specifically bind to p53 and suppress
p53-induced apoptosis [46]. Strong associations have
been observed between TP53 R249S mutation levels and
HCC risk, especially with respect to primary tumor
development and also the interval between surgical
resection and recurrence [47,48]. A recent study has
linked this p53 hotspot mutation to HCC with aggres-
sive tumors, poor prognosis and an acquisition of stem
cell-like traits[49], which is not unexpected since a sepa-
rate study has shown that TP53 mutations have the abil-
ity to reprogram terminally differentiated cells into
pluripotent stem cells[50].
Transcriptomic alterations: the deregulation of signaling
pathways in HCC
Structural genomic mutations and epigenetic changes
may lead to altered gene expression patterns that signifi-
cantly affect the signal transduction pathways in HCC
and the variability in pathway expressed may allude to
the cellular origin of HCC. A selection of the relevant
signaling pathways altered in HCC is discussed here
(Figure 1).
TGF-b is an inflammatory cytokine implicated in an
array of functions such as cell growth, differentiation,
migration, apoptosis, adhesion, survival and immunity
[51]. IGF-2R, a tumor suppressor gene, promotes the
degradation of mitogen IGF-2 and also the simultaneous
activation of transforming growth factor-b (TGF-b)s i g -
naling, thereby halting cell proliferation and carcinogen-
esis [52]. Inflammation and subsequent genomic
mutations in IGF-2R result in IGF-2 over-expression
and a reduction in the inhibitory effects of TGF-b sig-
naling, a feature commonly observed early in the devel-
opment of HCC [53,54]. Immunohistochemical analysis
of HCC has also revealed a disruption of TGF-b signal-
ing coinciding with an increase in the expression of
stem cell markers and the activation of interleukin-6
(IL-6). This indicates a link between IL-6, a major stem
cell signaling pathway and the disruption of TGF-b sig-
naling, resulting in CSC driven HCC[55].
Interestingly, IL-6 activation is a frequent event in
HCC. Recent studies indicate that gain of function
mutations of glycoprotein-130 (gp130), a co-receptor of
IL-6, is associated with a marked activation of IL-6 in
inflammatory hepatocellular adenomas[56]. Noticeably,
rare gp130 alterations are always accompanied by
b-catenin activating mutations in HCC, suggesting that
these two signaling pathways are converged to contri-
bute to hepatocarcinogenesis. Additional details about
b-catenin involvement in HCC are described below.
Wnt/b-catenin. This developmental pathway is com-
monly known for its fundamental role in embryogenesis,
which aids the cell in differentiation, proliferation and
apoptosis. In the absence of Wnt signaling, cytoplasmic
b-catenin complexes with the tumor suppressors: adeno-
matosis polyposis coli (APC) and Axin1, as well as the
glycogen synthase kinase-3b (GSK-3b). In this complex,
GSK-3b phosphorylates b-catenin, targeting it for ubi-
quitiniation and subsequent degradation. In the event
that Wnt signaling receptors are engaged, conforma-
tional changes in the Axin complex cause the release of
b-catenin, which then localizes to the nucleus and acti-
vates the transcription of Myc, cyclin D1 and COX2
amongst others [57-59]. In HCC, our studies and a
number of other transcriptomic and proteomic studies
have indicated an increase in Wnt signaling, possibly as
a result of an accumulation of Axin1 mutations at sites
that bind b-catenin and/or CTNNB1 mutations along
sites marked for phosphorylation by GSK-3b [60,61]. It
is hypothesized that an increase in signaling from the
Wnt pathway is necessary to maintain “stemness” in
HCC, characterized by cell proliferation and immortal-
ity, an event that may be representative of CSCs [60,62].
Myc is a potent oncogene, which appears to be consti-
tutively up-regulated in many human cancers, represent-
ing a phenomenon of “oncogene addiction.” Though
about 30% of HCC cases show an up-regulation of Myc
because of the Wnt/b-catenin pathway[63], its increased
expression in HCC is also attributable to the activation
of its locus through chromosome amplification [64] One
possible mechanism by which Myc contributes to hepa-
tocarcinogenesis is through the induction of telomerase,
which also appears to be active during HCC develop-
ment[65], thereby bypassing cellular senescence. More-
over, the up-regulation of Myc in a variety of tumors
has also been associated with deregulated microRNA
(miRNA) expression in many human malignancies [66],
which as discussed in the next section, have a significant
impact on tumorigenesis and progression. On the other
hand, the inactivation of Myc in HCC causes a subpo-
pulation of cells to differentiate while the rest remain
dormant, giving rise to a phenotypically diverse tumor
population and possibly the origin of CSCs [67].
PI3K/PTEN/Akt. The activation of the Akt pathway
is mediated by either an activated tyrosine kinase recep-
tor, or more rarely the constitutive activation of PI3K or
the loss of phosphatase and tensin homolog (PTEN).
P T E Ni sat u m o rs u p p r e s s o rg e n ea n dt h eP T E Np r o -
tein functions as a negative regulator of Akt. The loss of
PTEN expression via a loss of heterozygosity in chromo-
some 10q along with an activation of Akt has been
reported in 40%-60% of HCC cases [68,69]. Since Akt is
involved in a number of biological processes, such as
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its deregulation has been implicated in many human
cancers. Though the role of Akt in HCC is not con-
firmed, its activation is interestingly linked to more
aggressive tumors in HCC [70] and an activation of b-
catenin signaling in intestinal stem cells, suggesting that
the two oncogenic pathways: PI3K/PTEN/Akt and Wnt/
b-catenin may be interconnected to promote stemness
and carcinogenesis [71].
Aberrant expression of miRNAs in HCC
In recent years, the aberrant expression of miRNAs has
been implicated in a wide variety of human cancers.
miRNAs are a class of small non-coding RNAs that play
a critical role in biological processes of cell development
and differentiation and the deregulated expression of
miRNAs in HCC has revealed their functional involve-
ment in HCC carcinogenesis and progression [72].
For example, in HCC cases, gene expression profiling
reveals that an up-regulation of miR-181 is associated
with increased signaling in Wnt/b-catenin pathways and
conversely, siRNA mediated inhibition of the TGF-b
pathway indicates a decreased expression of miR-181
[73,74]. Moreover, loss of let-7g expression is associated
with HCC metastasis [75]. miR-26 expression has been
Figure 1 Signaling Pathways Altered in Hepatic Cancer Stem Cells.W n t / b- c a t e n i n ,P I 3 K / P T E N / A K T ,T G F - b/IGF-2R and IL-6/IL-6R/gp130
signaling pathways have been shown to be activated in HCC. Activation of the Wnt pathway results in b-catenin accumulation in the cytosol
and translocation into the nucleus, where b-catenin forms two major protein-DNA complexes. 1) b-catenin/TCF/LEF is a classic complex of Wnt/
b-catenin pathway that mediates Wnt target genes expression, e.g. EpCAM and miR-181; 2) EpICD/FHL2/b-catenin/LEF1-DNA complex represents
a cross-talk of Wnt/b-catenin with EpCAM signaling pathway [133]. Cleavage of EpCAM by TACE and PS-2 releases EpICD into cytosol which in
turn translocates into the nuclues with b-catenin and FHL2, where EpICD/FHL2/b-catenin forms protein-DNA complex with LEF1and regulates
EpCAM target genes expression, e.g. cyclin D1, c-Myc andd miR-181. AKT is activated by two phosphorylation sitess Thr308 and Ser473.
Phosphorylation of Thr308 is promoted by PI3K and suppressed by PTEN. Activated AKT induces cell survival through the suppressive
phosphorylation of BAD and Caspase 9, two apoptosis mediators in unphophorylated status. AKT also acts as a cell cycle progression regulator
through activating the mTOR pathway [134]. Two oncogenic pathways PI3K/PTEN/AKT and Wnt/b-catenin may be interconnected to promote
stemness and carcinogenesis. Loss of IGF-2R impacts cell proliferation by accumulating IGF-2 mitogen and activation of TGF-b signaling.
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silencing of miR-26 in tumor cells is linked to a subtype
of HCC with an activated inflammatory pathway and a
favorable response to interferon therapy [76]. In addi-
tion, increased expression of miR-21 has been associated
with loss of heterozygosity at the PTEN locus, conse-
quently activating the Akt pathway and promoting
tumorigenesis [77,78]. Similarly, miRNAs associated
with the cell cycle regulation and apoptosis inhibition in
HCC have also been identified [79].
A study in our lab has revealed a 20-miRNA-based
signature that is associated with HCC venous metasta-
sis, details of which are expanded upon at the end of
this article. This signature provides promise to a future
of personalized medicine since it can be used clinically
to identify patients with early-stage disease or metas-
t a s e sa n dc a ne v e nb eu s e dt o predict survival and
recurrence [80].
Epigenetic modifications may improve the early detection
of HCC cases
In the last decade there has been increasing evidence to
support the occurrence of aberrant DNA methylation
patterns in human HCC [27]. Therefore, in addition to
genetic mechanisms of deletions or mutations, epige-
netic changes can increase or decrease gene expression
via regulating DNA methylation. DNA methylation in
the mammalian genome is found at the cytosine resi-
dues of CpG dinucleotides, often associated with pro-
moter-related CpG islands. Though methylation is
imperative for normal development and differentiation,
aberrant hypomethylation in HCC and many human
cancers can lead to the expression of oncogenes [81], or,
similarly, hypermethylation can lead to the silencing of
tumor-suppressor genes [82]. In HCC, an increased
expression of DNA methyltransferases (DNMTs),
enzymes which catalyze epigenetic alterations, occurs
early in the development of tumorigenesis. The fre-
quency of aberrant DNA methylation increases from
precancerous lesions to dysplastic nodules and finally
HCC, signifying their important role in tumor progres-
sion [83]. For instance, the tumor suppressor genes: RB1
[84] and CDKN2A [36] have been shown to be hyper-
methylated in HCC, leading to uncontrolled cell prolif-
eration. Likewise, PTEN promoter methylation has also
been reported in HCC, which allows the progression of
the PI3K/PTEN/Akt pathway [85].
Epigenetic changes in HCC have also been reported at
the miRNA level. For example, the deregulation of miR-
1 due to hypermethylation in HCC was reversed with
5-azacytidine, resulting in decreased cell proliferation
and increased apoptosis [86]. A similar association has
been observed with miR-124 and also miR-203, amongst
others, in HCC [87].
Since distinct methylation signatures of tumor sup-
pressor genes have been observed in high-risk subjects
up to 9 years before clinical diagnosis, DNA methylation
profiling may provide a unique tool to reliably predict
cancer status. Apart from their potential as a diagnostic
platform though, further understanding of methylation
patterns in HCC may provide them useful in determin-
ing recurrence and survival, as well [88].
Transcription profiles and the identification of HCC tumor
subtypes
Recent breakthroughs in technology have provided com-
prehensive genetic and transcriptomic profiling platforms
that are successfully used in identifying tumor subtypes
and predicting patient outcome and survival. In addition
to classifying tumor aggressiveness, high-throughput
molecular profiling systems are also useful in determining
how the tumor will respond to treatment.
Global gene expression analysis of HCC has revealed
two distinctive subclasses of human HCC that are highly
associated with patient survival [89]. The low survival
subclass was marked by increased expression of cell pro-
liferation and antiapoptotic genes, such as PCNA and
PTMA, respectively. Moreover, the poor survival sub-
group also expressed a higher number of genes related
to ubiquitination and histone modification, namely
UBE2D1 and HRMT1L2, respectively.
Additional transcriptome analysis of HCC samples has
classified HCC into 6 subgroups associated with clinical
and genetic characteristics, which further identify two
tumor groups linked to chromosome instability (Groups
1-3) or stability (Groups 4-6) [90]. The first group was
linked to low copy number HBV infection, particularly
in Africa, increased Axin 1 mutations, absence of TP53
mutations and possessed an over expression of
imprinted genes. The second group was linked to high
copy number HBV infection, many regions of LOH, and
TP53 and Axin1 gene mutations. These first two groups
are the only ones that employed the Akt biological path-
way and appeared most genetically distinct from the
remaining subgroups. Groups 5 and 6 were also sub-
stantially different since they were easily classified based
on the abundance of CTNNB1 mutations (near 100%)
and the high level of Wnt pathway activation.
Recently, our lab identified another 2 HCC subtypes
based on their expression of a hepatic stem cell marker,
epithelial cell adhesion molecule (EpCAM) and EpCAM-
coexpressed genes[91]. EpCAM-positive HCC correlated
with increased Wnt pathway activation, cytokeratin 19
and c-Kit, which are all known markers of progenitor
cells. On the other hand, EpCAM-negative HCC
resembled gene expression patterns of mature hepato-
cytes. Further analysis based on AFP levels allowed these
two subgroups to be further divided into 4 subtypes with
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tion, poor clinical outcome is correlated with AFP
expression and good prognosis was only associated with
EpCAM
+ AFP
- cases.
Insights into tumor response to treatment are being
elucidated and our lab recently identified the impor-
tance of miR-26a and miR-26b in survival and response
to interferon therapy [76]. Compared to paired noncan-
cerous tissue, HCC samples had decreased miR-26
expression correlating with an increase in nuclear factor
B( N F - B) and IL-6 signaling. Furthermore, clinical
data revealed that those patients with low miR-26
expression had a better response to adjuvant interferon
therapy with interferon alpha than those with high miR-
26 expression.
Taken together, transcriptional profiling platforms are
beginning to provide a vast amount of useful informa-
tion that can be synthesized to identify HCC subtypes,
patient outcome, and survival and treatment options.
Still, new insights into the potential cellular origin of
HCC and its activated molecular pathways are necessary
to improve targeted therapy.
Two models of hepatocarcinogenesis may complement
one another
The longstanding clonal evolution model for HCC
development is a multistep event, which may take 30
years to unfold. As described earlier, the various etiolo-
gical factors, particularly inflammation and viral hepati-
tis, appear to contribute significantly to approximately
90% of HCC cases by creating phenotypically altered
hepatocytes. The stepwise progression from altered
hepatocytes to dysplastic nodules, or precancerous
lesion, occurs as a consequence of chronic inflammation
and genomic alterations, which commonly precede HCC
[27,39,92]. Therefore, the accumulation of genetic and
epigenetic changes, such as the loss of tumor suppressor
genes and the gain of an oncogene, gives rise to a mass
of primary tumor cells that are considered monoclonal
in origin[92,93]. Though from a scientific standpoint
this model has vastly improved our understanding of
the various genetic and signaling events underlying
HCC development, it is unfortunate that these findings
have not been translated into better treatment options
as liver resection and transplantation still remain the
best choice and only benefits a small population.
A more recently proposed stem cell model for HCC
tumorigenesis may provide a more personalized approach
to address diagnostic and therapeutic strategies in the
clinic (Figure 2). This model hypothesizes that HCC
could be derived from progenitor cells or de-differen-
tiated transformed cells; based on the observation that
embryonic stem cells (ESC) and CSCs behave similarly.
This would be able to explain the heterogeneous nature
of HCC morphology, clinical behavior, and molecular
profiles [60,94]. Since the liver is an organ with regenera-
tive capacity, it has bi-potential progenitor cells that can
give rise to hepatocytes or chloangiocytes, which could
possibly develop into HCC or ICC, respectively [95,96].
Furthermore, cases with a mixed morphology have also
been identified. Based on the expression of EpCAM, a
substantial number of HCC cases consist of progenitor
cells and their heterogeneous progeny with a capacity to
self-renew and limitlessly divide [60,91,94]. This relatively
new hypothesis is not intended to be contradictory to the
step-wise model, but merely complementary in explaining
the origin of a more comprehensive group of HCC cases
and the arising issues in diagnosis and treatment.
For example, mature hepatocytes, cholangiocytes or
bi-potential progenitor cells that acquire mutations
through random genetic or epigenetic events can intro-
duce a genetic imbalance in the primary tissue, resulting
in the de-differentiation of mature cells and the loss of
cell cycle control and/or the ability to continuously self
renew. Depending on the extent of genetic alterations,
the tumor cells may remain benign or develop and
metastasize. Therefore, events initiated by the multistep
carcinogenesis model can also result in heterogeneous
tumors with stem cell capability and the potential to be
more aggressive.
Intrahepatic Cholangiocarcinoma
An increasing global incidence of ICC [5] has recently has-
tened research in this field to understand the mechanisms
underlying pathogenesis of this dreadful disease. Reviewing
the mechanisms of ICC indicates that similarities can be
drawn between ICC and HCC, which may improve the
prospects of this disease in a clinical setting. Particularly,
the tumorigenesis models proposed for ICC development
are remarkably similar to those for HCC. Furthermore,
several histopathologic and gene expression profiling stu-
dies have shown PLC tumors that exhibit a combination
of HCC and CCA traits, suggesting an overlap between
these tumor types. A subtype of tumors showing com-
bined characteristics of hepatocellular-cholangiocarcinoma
(CHC) have been reported and proposed to develop from
the bi-potential liver stem cells [97]. Even more recently, a
new subtype - cholangiocarcinoma-like HCC (CLHCC)
-was discovered and characterized as HCC expressing
CCA-like traits. The heterogeneity observed between all
4 tumor subtypes could be indicative of their cellular ori-
gins from different developmental stages and may also
represent a novel way to approach targeted therapy in
CCA and HCC [98].
Comparable to HCC, ICC most commonly arises in
the setting of chronic inflammation, often within bile
ducts [99] and likely due to liver fluke Opisthorchis
viverrini infestation [100], PSC[101] or hepatolithiasis
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kines and the induction of inducible nitric oxide
synthase (iNOS) lead to oxidative and nitrosative DNA
damage [100], increased cell turnover and inhibition of
DNA repair mechanisms [103]. In the stepwise model,
an accumulation of inflammatory-mediated genetic and
epigenetic alterations has been proposed to lead to the
successive development of ICC from biliary epithelial
cells to biliary dysplastic lesions and eventually cancer
[104].
There is growing evidence supporting a hepatic stem
cell model of cholangiocarcinoma [96,105,106]. Interest-
ingly, the same bi-phasic progenitor cell can give rise to
hepatocytes and cholangiocytes, as mentioned earlier,
and each of these cells has longevity and repopulating
potential [107]. Therefore, in the setting of chronic
Figure 2 Cancer Stem Cell Model for HCC Tumorigenesis. The generation of a CSC model will more effectively benefit the clinical treatment
of HCC patients, allowing therapy directed at the most aggressive cells. So far, there is no compelling data demonstrating that HCC follows this
model. To test the CSC model, at least two terms have to be addressed: 1) The vast majority of HCC cells, excluding the small subpopulation of
CSCs, lack tumorigenic capacity; 2) These CSC populations are distinguished by epigenetic rather than genetic differences because the CSC
model argues that CSCs undergo hierarchical differentiation and the epigenetic changes are irreversible. Two HCC subgroups were recently
identified based on the expression of AFP and EpCAM. EpCAM
+AFP
+ HCC subgroup (HpSC-HCC) had the features of hepatic stem/progenitor
cells and EpCAM
-AFP
- HCC subgroup (MH-HCC) featured as matured hepacytes. HpSC-HCC displayed the ability to self-renew, differentiate and
also generate highly invasive HCC. Based on these observations, it is plausible that HCC may represent another solid cancer type that follows the
CSC model besides breast, brain and colon cancers. Consistent with the clonal evolution model, HCC CSCs can arise from the mutation of
normal hepatic stem/progenitor cells. Though there has not been evidence showing that HCC CSCs can arise from differentiated hepatocytes,
the possibility still exits, as there are examples of this in hematopoietic malignancies. Overall, not in contrast to the clonal evolution model, an
accumulation of mutations during the normal development of hepatocytes as a consequence of exposure to the various risk factors of HCC
might contribute to the rise of the hepatic CSCs; therefore the two models do not contrast but complement each other.
Kumar et al. Cell & Bioscience 2011, 1:5
http://www.cellandbioscience.com/content/1/1/5
Page 7 of 13inflammation, a tumor could arise from the clonal evo-
lution of either mature cholangiocytes which de-differ-
entiate, or progenitor cells; allowing a combination of
the two proposals. Furthermore, depending on the
degree of differentiation achieved before maturation
arrest, one can observe a heterogeneous tumor with a
range of neoplastic phenotypes [107]. One author
explains that the dysplastic nodules observed during car-
cinogenesis may be adaptive non-oncogenic responses to
carcinogenic substances, rather than a multistep accu-
mulation of genomic alterations [105].
Genetic alterations that manifest in ICC
Genomic alterations
In a study aimed at distinguishing chromosomal changes
between HCC and ICC, CGH analysis reveals the fre-
quency of chromosomal losses in ICC is higher [53].
Short segments of chromosomes 1p [108], 3p, 6q and
9q [28,108] are commonly deleted in ICC, with a fre-
quency of at least 55%, whereas the frequency of such
events in HCC are usually less than 40% [28]. Com-
monly amplified regions in ICC are in segments of 1q,
7q, 7p and 8q [28,108], with an amplification frequency
of at least 30%. Losses in regions of 6q and 3p appear to
be highly characteristic of cholangiocarcinoma, but over-
all the high frequency of gains and losses appears to
c a r r yap o o rp r o g n o s t i cv a l u e[28]. Further studies to
detect the loss of tumor suppressor genes during a con-
sistent LOH have indicated a high rate of allelic losses
at 5q and 17p [109,110]. LOH has been observed in
other chromosomal regions, but to a lesser extent, and
may represent random error. HCC and ICC share simi-
lar allelic losses in the 5q and 17p regions, allowing
some to propose that these two tumors arise from the
same CSC and therefore may share similar genetic
changes during tumorigenesis [105,110]. Persistent
structural genomic changes in these cells have been
associated with a variety of mutations, conferring a loss
in tumor suppression and the amplification of oncon-
genic pathways.
TP53 mutations in ICC are common and their fre-
quency ranges from 20-80% depending on the geo-
graphic region [111,112]. Though the deregulation of
p53 in ICC is similar to HCC, as there is a loss of cell
cycle control and a decrease in apoptotic events, the
deregulation in ICC is sometimes more associated with
an accumulation of inactive wild-type p53 and its inhibi-
tor mdm-2, rather than a loss of function mutation
[113,114]. This renders the p53 regulatory pathway non-
functional and supports the notion that either TP53
mutations or an alteration to the p53 pathway may be
critical to the development of ICC [115,116]. The regu-
lation of cell cycle entry by p53 involves, amongst
others, the p21
WAF1/Cip1 protein, which binds to the cell
division kinase (CDK) 4:cyclin D complex and prevents
the phosphorylation of Rb protein. The CDK4:cyclin D
complex is also influenced by the p16
INK4A inhibitory
protein[117], which coincidentally is altered by LOH
and/or promoter hypermethylation in 25%-83% of
resected cholangiocarcinoma specimens [118,119].
K-ras mutations occurring at codon 12 are often
observed in ICC, involving either a glycine to aspartic
acid or a glycine to cystine transition [111,115]. Less fre-
quent mutations have been observed in codon 13 (sec-
ond nucleotide) and codon 61 (third nucleotide) [120].
K-ras mutations corresponding to over expression are
observed early in carcinogenesis, which suggests an
important role in ICC development. Furthermore, K-ras
has been implicated in aggressive ICC downstream of
the biliary tree with increased expression levels in meta-
static lymph nodes [121]; therefore K-ras expression
correlates to poor prognosis [122].
Transcriptomic alterations: Enhanced proliferation signaling
in ICC
The inactivation of tumor suppressor genes and the
concordant amplification of proto-oncogenes, such as
TP53 and K-ras, respectively, play a significant role in
altering the signaling network and promoting tumori-
genesis. The exact mechanism by which these pathways
are affected is currently unknown, especially since most
of the mechanisms have only been observed in ICC cell
lines. Since in vivo studies in animal models poorly cor-
relate with clinical outcome, the need to recreate an
ICC model to better understand this disease is under-
scored. Despite this lack of conclusive data, several stu-
dies have identified a selection of important
mechanisms contributing to the development of ICC,
emphasizing the role of TGF-b, IL-6, STAT-3, COX-2
and b-catenin [99,123]. Because of the similarities
already observed in the etiology and structural changes
between HCC and ICC, and since some pathways most
likely overlap, one may try to infer the mechanisms
underlying HCC on ICC and compare this with gene
expression arrays to arrive at a more functional under-
standing of molecular pathogenesis in ICC.
Transcriptomic alterations: the recent identification of
miRNAs in ICC
Just as in HCC, the altered expression of miRNAs in
ICC has been reported to contribute to tumor growth.
Malignant cholangiocytesa p p e a rt ob em a r k e db ya n
over-expression of miR-21, miR-141 and miR-200b
[124]. The increased expression of miR-21 and miR-
200b has been linked to increased cellular proliferation,
mediated by a down-regulation of PTEN and ZFHX1B
tumor suppressors, respectively [78,124]. In addition, the
decrease in miR-29b has been linked to the increased
expression of MCL-1, an anti-apoptotic protein, result-
ing in decreased apoptosis [125]. Though the network of
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miRNAs in ICC is likely to lead to novel diagnostic and
prognostic methods once their function is confirmed.
Future Perspectives
Currently, surgery such as liver resection remains the
best treatment option for early HCC and ICC but tumor
recurrence is still predominant in about 80% of HCC
cases [126] and may be higher in ICC cases [127]. To
make matters worse, effective treatment is limited for
advanced stage carcinoma, which emphasizes the need
to improve our understanding of primary liver cancers
and consequently help improve patient diagnosis during
the early stage. Intervention early in the process will
improve treatment and prognosis, which may be con-
ferred by an attempt at personalized medicine.
Individual genetic background has been suggested to
contribute to HCC risk, given that only a fraction of
patients with chronic liver disease or PSC actually
develop HCC or ICC, respectively, even though greater
than 50% of cases occur in the setting of inflammation.
For this reason, the identification of genetic susceptibil-
ity loci and new biomarkers are essential to improving
diagnosis and treatment outcome, and GWAS studies in
liver cancer are highly necessitated.
The hypothesized CSC model for the development of
HCC and ICC, and the molecular pathways, such as the
Wnt/b-catenin pathway and miR-181, provide valuable
information about tumor growth and invasiveness. Since
recently, the role of EpCAM in maintaining a stem cell phe-
notype in HCC and ICC is being elucidated but our studies,
as well as others provide evidence for its role in the promo-
tion of proliferation, migration and invasion potential in
cells with activated Wnt/b-catenin signaling [60,91,128].
Therefore, b-catenin may be a novel target in the preven-
tion of carcinogenesis [57], highlighting the importance of
molecular profiling to characterize the population of cells
and their distinct molecular pathways [60].
The role of miRNA signatures has recently been eluci-
dated through the examination of miRNA expression
profiles of samples from two different subtypes in HCC,
indicating miRNA profiling can be used to indicate
tumor origin and aggressiveness. In these studies
[60,91,129], the two subtypes are hepatic stem cell like
HCC (HpSC-HCC; EpCAM
+AFP
+) and mature hepato-
cyte like HCC (MH-HCC; EpCAM
-AFP
-), where HpSC-
HCC cells are hepatic CSCs with the ability to self-
renew, differentiate and initiate aggressive tumors in
vivo [60]. Coincidentally, among HpSC-HCC tissues,
miR-181 is found to be up-regulated and functions in
promoting stemness by targeting hepatic transcriptional
regulators of differentiation, such as CDX2 and GATA6,
and nemo-like kinase (NLK), an inhibitor of Wnt/b-
catenin signaling [73].
The exciting identification of miRNA signatures
unique to HCC offers new platforms for cancer diagno-
sis and prognosis. For instance, in addition to the 20-
miRNA-based signature described above that is able to
differentiate between CSC-like and mature hepatocyte-
like HCC tumors, there are additional miRNAs that can
help differentiate between benign and malignant tumors,
or between alcohol induced or HCV induced HCC
[130]. Prognostic miRNA markers of HCC also exist,
and in fact they are specific enough to help with deter-
mining metastasis [80], recurrence [131] and survival
[75,76,80], independently.
Studies have also indicated the therapeutic potential of
miRNAs, particularly with the observance that anti-miR-
181 can reduce tumorigenicity in mice with hepatic CSCs,
cells that are otherwise resistant to chemotherapy with 5-
Fluorouracil (5-FU) [60]. Along with others, our studies
indicate that miR-26 functionally acts as a tumor suppres-
sor by inhibiting cell proliferation, and a low miR-26
expression is associated with poor prognosis [76]. miR-26
expression is significantly down-regulated in HCC, but
gene therapy with the delivery of miR-26 to hepatocytes
considerably blocks Myc-induced HCC [76,132]. Further-
more, studies in our lab on miR-26, NF-B and IL-6 have
revealed the potential of miRNA expression profiles in the
stratification of patients for interferon therapy [76].
Conclusion
The studies of molecular mechanisms involved in the
progression to HCC have been investigated at length,
and they have helped infer testable hypotheses in ICC.
Advances in molecular profiling studies using DNA-
microarray based gene-expression profiling have pro-
vided increased awareness about the regulatory networks
altered in human HCC and have also provided useful
gene expression-based signatures that can distinguish
tumor subtypes, assist clinical staging and predict
patient outcomes. Since molecular profiling is proving
to be an efficient way to gain insight into the molecular
mechanisms underlying carcinogenesis, these techniques
should also be employed more extensively in ICC so
that we can obtain a more inclusive picture of regula-
tory elements in pathogenesis.
Advances in the specificity and sensitivity of molecular
profiling platforms including expression analysis and
comparative genomics with the additional incorporation
of PLC databases and bioinformatics tools, we are
approaching a new era for understanding the heteroge-
neity of HCC and ICC tumors. Such integrated plat-
forms are enabling our improved understanding of the
etiology, tumor microenvironment and the carcinogen-
esis of these two devastating diseases, which we hope to
integrate with a personalized approach in improving the
clinical outcome of these cases.
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